Proprotein convertase subtilisin/Kexin Type 9 (PCSK9) inhibitors are widely used in patients with acute myocardial infarction due to their potent low‐density lipoprotein‐lowering effects. The gene discussed is PCSK9; the disease is myocardial infarction.